| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
* From the Departments of Anesthesiology, and
Medical Biology, Centre hospitalier affilié universitaire de Québec, Université Laval, Québec City, Québec, Canada.
Address correspondence to: Dr. Martin R. Lessard, Département d’anesthésie-réanimation, Hôpital de l’Enfant-Jésus du CHA, 1401, 18e rue, Québec City, Québec G1J 1Z4, Canada. Phone: 418-649-5807; Fax: 418-649-5918; E-mail: martin.lessard{at}anr.ulaval.ca
Purpose: Norepinephrine (NE) infusions are commonly used in the intensive care unit and in the operating room. Data on long term stability of NE solutions are lacking. This prospective study was designed to evaluate the stability of NE, in dextrose (5%) in water (D5W) and in normal saline (NS) solutions, for a period up to seven days.
Methods: We prepared norepinephrine solutions in quadruplicate, by aseptically diluting 1 mg NE in 250 mL of D5W or NS and 4 mg NE in 250 mL of D5W or NS (final concentrations, 4 µg·mL–1 and 16 µg·mL–1, respectively) and stored the solutions at room temperature under ambient light. We sampled the solutions, in duplicate, at times 0, 24, 48, 72, 120, and 168 hr and stored them at –80°C for later assay. Norepinephrine concentrations were measured by high-performance liquid chromatography with electrochemical detection (coefficient of variation 4.6%). Statistical analysis was done by nonparametric, repeated measures ANOVA (Friedman test).
Results: There was no significant decrease in NE concentration for either, NE 4 µg·mL–1 in D5W or NS (P = 0.09 and 0.11, respectively) or for NE 16 µg·mL–1 in D5W or NS (P = 0.18 and 0.40, respectively). The ratios of NE concentration at 168 hr, compared to baseline, were 95.7% and 96.4%, for NE 4 µg·mL–1 in D5W and NS, respectively, and 104.5% and 96.4%, for NE 16 µg·mL–1 in D5W and NS, respectively.
Conclusion: Norepinephrine solutions, in concentrations commonly used in the clinical setting, are chemically stable for seven days, at room temperature and under ambient light, when diluted either in D5W or NS.
1 Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004; 32: 1928–48.[Medline]
2 Ogle CW. Noradrenaline in the tropics. Br Med J 1968; 2: 490.[Medline]
3 Hugues IE, Smith JA. The stability of noradrenaline in physiological saline solutions. J Pharm Pharmacol 1978; 30: 124–6.[Medline]
4 West GB. The stability of noradrenaline solutions. J Pharm Pharmacol 1952; 4: 560–5.[Medline]
5 Newton DW, Fung EY, Williams DA. Stability of five catecholamines and terbutaline sulfate in 5% dextrose injection in the absence and presence of aminophylline. Am J Hosp Pharm 1981; 38: 1314–9.[Abstract]
6 Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther 1991; 16: 337–40.[Medline]
7 Peddicord TE, Olsen KM, ZumBrunnen TL, Warner DJ, Webb L. Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride and nitroglycerin in 5% dextrose injection. Am J Health Syst Pharm 1997; 54: 1417–9.
8 Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994; 51: 1802–7.[Medline]
9 Baumgartner TG, Knudsen AK, Dunn AJ, et al. Norepinephrine stability in saline solutions. Hosp Pharm 1988; 23: 44–59.
10 Trissel LA. Handbook of Injectable Drugs, 13th ed. Bethesda: American Society of Health-System Pharmacists; 2005.
11 Vogelzang M, Nijboer JMM, van der Horst IC, Zijlstra F, ten Duis HJ, Nijsten MW. Hyperglycemia has a stronger relation with outcome in trauma patients than in other critically ill patients. J Trauma 2006; 60: 873–9.[Medline]
12 van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359–67.
13 Trissel LA. Avoiding common flaws in stability and compatibility studies of injectable drugs (Editorial). Am J Hosp Pharm 1983; 40: 1159–60.[Medline]
14 Autonomic drugs. In: McEvoy GK, Snow EK, Kester L (Eds). AHFS Drug Information 2006, 1st ed. Bethesda: American Society of health-system pharmacists; 2006: 1344–6.
15 Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA 2003; 290: 2041–7.
16 Meisler JM, Skolaut MW. Extemporaneous sterile compounding of intravenous additives. Am J Hosp Pharm 1966; 23: 557–63.[Medline]
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
